Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesWilliam J. Sandborn, Brian G. Feagan, Timothy E. Ritter et al.|The Lancet|2023Cited by 350
968a: ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALSWilliam J. Sandborn, Brian G. Feagan, Séverine Vermeire et al.|Gastroenterology|2022Cited by 8
S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12Brian G. Feagan, Silvio Danese, Laurent Peyrin‐Biroulet et al.|The American Journal of Gastroenterology|2022Cited by 2